Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionise treatment for age-related macular degeneration (AMD).
AMD is the leading cause of blindness in the developed world. Its prevalence is increasing dramatically as the population ages and it is estimated that, by 2020, there will be about 200 million people worldwide with the condition. In the UK alone, there are over 500,000 people with late stage AMD.
AMD is currently treated by injections of sight-saving drugs into the eye which must be administered by medical professionals. Scientists led by biochemist Dr Felicity de Cogan, from the University of Birmingham’s Institute of Microbiology and Infection, have invented a method of delivering these otherwise-injected drug as eye drops.
Laboratory research, published last year in Investigative Ophthalmology & Visual Science (IOVS), showed that these eye drops have a similar therapeutic effect as the injected drug in rats. Now the Birmingham scientists have taken their research one step further by investigating the effect of the eye drops in the larger eyes of rabbits and pigs, which are more similar to human eyes.
This latest study, also published in IOVS, demonstrates that the eye drops can deliver a therapeutically effective amount of the drugs to the retina of the larger mammalian eye.
The technology behind the eye drops is a cell-penetrating peptide that can deliver the drug to the retina (the back of the eye). The scientists’ pending patents for the eye drops are now owned by US-based company, Macregen Inc, and a team of Birmingham researchers is working with the company to develop a novel range of therapies for AMD and other eye diseases.
The combined team is now expediting proof of concept studies to confirm the validity of the therapeutic approach. Clinical trials will be imminent once these studies are completed, and could start as early as spring 2019.
Dr de Cogan said: “For several years, our team has focused on the challenge of delivering drugs to the back of the eye.
“From the outset, we realised that delivering drugs through eye drops would mean that patients can administer their treatment themselves, and this would be less costly, save time for patients and healthcare providers, and reduce the potential complications that can arise from injections.
“Now we have shown that the eye drops work in the larger mammalian eye, and we welcome the commercial investment and expertise from Macregen so we can deliver a structured research and development programme that should bring concrete benefits to people with AMD and eye diseases.”
Professor Robert Scott, Consultant Ophthalmologist and Honorary Professor of Ophthalmology at University of Birmingham, commented: “Cell-penetrating peptides will drive the next generation of treatment for people with AMD.
“They will be transformative for patients who currently have to organise their lives around monthly clinic visits for uncomfortable intraocular injections, who will in the future have the convenience of self-administering their medical treatment.”
Keith Roizman, Founder, Executive Chairman, and Chief Technology Officer of Macregen, said: “Macregen and the company’s prospective strategic partners and licensees are expected to make significant investments in laboratory proof of concept studies, the subsequent research and development programmes and clinical trials.
“We will also pursue the necessary and required regulatory programmes to make these eye drops available to patients.”
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- First gene therapy operation for macular degeneration is a success on February 20, 2019 at 3:20 am
The treatment is the first to target the underlying genetic cause of age-related macular degeneration (AMD), which affects more than 600,000 people in the UK alone. An 80-year old woman is the first o... […]
- Qatar- What is wet macular degeneration on February 19, 2019 at 3:19 pm
(MENAFN - Gulf Times) Millions of people deal with age-related macular degeneration as they get older, but many don't understand the difference between types of the condition or what they can do ... […]
- Experimental gene therapy aims to stop age-related macular degeneration on February 19, 2019 at 8:19 am
(Gray News) – For the first time, a woman with the most common cause of blindness – age-related macular degeneration – has been treated with an experimental gene therapy in the hopes it will halt the ... […]
- What is wet macular degeneration on February 18, 2019 at 12:53 pm
Millions of people deal with age-related macular degeneration as they get older, but many don’t understand the difference between types of the condition or what they can do to lessen the effects. Dr S... […]
- Is a cure for blindness in sight? Scientists launch first attempt to halt most common cause of age-related blindness with gene therapy on February 18, 2019 at 6:36 am
Now the surgeons have launched their first attempt at halting age-related macular degeneration - known as AMD - which is the most common cause of blindness and affects 600,000 people in the UK. The te... […]
- Macular Degeneration on February 17, 2019 at 1:50 pm
Age-related macular degeneration (AMD) is a chronic disease of the macula, the central area of the retina, and is the leading cause of irreversible vision loss in the developed world. AMD is classifie... […]
- Protect Your Aging Eyes From Macular Degeneration on February 15, 2019 at 2:00 pm
FRIDAY, Feb. 15, 2019 (HealthDay News) -- Age-related macular degeneration (AMD) is an incurable eye disease that affects millions of older Americans, but there are a number of things you can do to re... […]
- What you need to know about wet macular degeneration on February 14, 2019 at 6:35 am
Millions of people deal with age-related macular degeneration as they get older, but many don't understand the difference between types of the condition or what they can do to lessen the effects. […]
- Top 7 Healthy Habits to Help Prevent Macular Degeneration on February 12, 2019 at 8:17 pm
Doctors aren't sure what causes age-related macular degeneration, a disease that affects millions of people in the United States. Also called AMD, it is known for causing blurred central vision due to ... […]
via Bing News